Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)

NCT00297115 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1568

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: Roflumilast
DRUG: Placebo

Sponsor

AstraZeneca